| Document |
Document Title |
|
WO/2023/164680A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditi...
|
|
WO/2023/161172A1 |
The present invention relates to substituted N-benzoic acid uracils of general formula (I) or salts thereof, wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof as he...
|
|
WO/2023/138478A1 |
Disclosed are a solution type nasal spray containing 3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypro
pyl)-1-azabicyclo[2,2,2]octonium salt or a derivative thereof, and a preparation method therefor. The components of the sol...
|
|
WO/2023/138526A1 |
Provided is a crystal form of an allyl-containing methylpyridopyrimidine compound, and in particular crystal forms of a compound as shown in formula (I) and of a salt of the compound.
|
|
WO/2023/134677A1 |
The present application relates to a method for preparing a pyrrole compound and an intermediate thereof. The pyrrole compound and/or the intermediate thereof can be used for preparing a pyrrole amide compound serving as a mineralocortic...
|
|
WO/2023/110138A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/114365A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2023/077218A1 |
There is provided a process for alkylating a substrate with a photocatalytic system. The process comprises providing a mixture containing an acid, and a substrate (an organic compound). Then, an organophotoredox catalyst of formula Ia is...
|
|
WO/2023/063722A1 |
The present invention relates to: a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof; a method for preparing the compound; and a pharmaceutical composition for preventing or treating diabetic perip...
|
|
WO/2023/011540A1 |
A fused ring compound, a pharmaceutical composition, and an application thereof. Provided is a fused ring compound shown in formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and good SOS1 inhibit...
|
|
WO/2023/002984A1 |
The present invention addresses the problem of providing: a method for producing a fluorinated imidazole with a good yield; and a method for producing an imidazole compound having a high optical purity. As a result of diligent research...
|
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/275333A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2022/259267A1 |
The present invention relates to a safer, easier and cost-effective method for preparing L-glufosinate or salts thereof. The present invention further relates to a novel L-glufosinate quinine tetrahydrate salt and its use in a method for...
|
|
WO/2022/240116A1 |
The present invention provides a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically...
|
|
WO/2022/215083A1 |
The present invention relates to solid state forms of (S)-quinuclidin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-ylcarbamate represented by the following structural formula.
|
|
WO/2022/212531A1 |
Disclosed are compounds of formula (I): (I). Variables R1-R4, R4a, A, U, V, X, and Y and ring W are defined herein. Also disclosed are a pharmaceutical composition containing such a compound and methods of using the compound for treating...
|
|
WO/2022/175402A1 |
The invention relates to certain substituted quinuclidine-3-one compounds for use in the treatment of hyperproliferative disease, such as cancer, and diseases associated with inflammation. More particularly, the present invention relates...
|
|
WO/2022/166974A1 |
A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibit...
|
|
WO/2022/165607A1 |
An oral film dosage form with high loading of active pharmaceutical ingredients, comprising a suspending agent/viscosity increasing agent, a mucoadhesive film former, an amphiphilic solubility enhancer, a non-amphipathic solubility enhan...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
|
WO/2022/133362A1 |
Disclosed are facile methods of purifying a cannabis extract to produce highly purified, crystallized cannabinoid acids, and in particular cannabinoid acids such as THCA, and removing impurities from the same, by using polar aprotic solv...
|
|
WO/2022/115879A1 |
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.
|
|
WO/2022/081742A1 |
Disclosed herein are methods of treating a complication of a hemoiysis and/or an inflammasome activation-associated disease comprising administering to a patient in need thereof quinine, or a derivative or sait thereof, or the combinatio...
|
|
WO/2022/069509A1 |
The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1- yl)-acetamide derivatives as potent inhibitors of transforming growth factor-β receptor I, (also named activin receptor-like kinase 5) (TGFβRI)/ALK5. O...
|
|
WO/2022/017519A1 |
A quinazoline compound and a pharmaceutically acceptable salt thereof, in particular a compound of formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/261498A1 |
A composition which contains a cyclic ether component, a thiol component, and a compound represented by general formula (1). It is preferable that the content of the cyclic ether component is from 20 parts by mass to 80 parts by mass in ...
|
|
WO/2021/260029A1 |
The present invention relates in its broadest aspect to a compound of Formula I as provided herein, formulations comprising such a compound and corresponding uses thereof for the reduction of infestation with ectoparasites, in particular...
|
|
WO/2021/261497A1 |
The present invention provides a compound represented by general formula (1). (In the formula, Ar is an aromatic ring group having two or more ring structures, A is a group having a quinuclidine skeleton, B- is a monovalent anion, and R1...
|
|
WO/2021/228673A1 |
The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I) wherein the variables are as defined in the specification, and the shown enantiomer has at least 75% ee; by oxo-Michael addition of ...
|
|
WO/2021/218833A1 |
The main purpose of the present invention is to provide a novel crystal of a quaternary ammonium salt structure compound, i.e., (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-ph
enoxypropyl)-1-azabicyclo[2,2,2]octylonium bromi...
|
|
WO/2021/215537A1 |
The present invention addresses the problem of providing a 2-heteroarylaminoquinazolinone derivative. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [in the formula, X1 ...
|
|
WO/2021/172359A1 |
Provided is a novel CDK9 inhibitor prodrug and a liposome that includes the same. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a liposome that includes the same. ...
|
|
WO/2021/158948A1 |
The disclosure includes compounds of Formula (I) and Formula(A) wherein R1, R2, R3, m, n, k, and L are defined herein. Also disclosed are methods for treating a neoplastic disease, autoimmune disease, or an inflammatory disorder with the...
|
|
WO/2021/158640A1 |
The claimed invention refers to a crystalline form B of 3-((lR,5S,9r) -9-ethoxy-3-azabicyclo[3.3.1]nonan-9-yl)-benzamide hydrochloride as mu-opioid receptor (MOR) agonist for the treatment of pain. (I) The crystalline form B is character...
|
|
WO/2021/113365A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo...
|
|
WO/2021/032934A1 |
The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.
|
|
WO/2021/013800A1 |
The invention relates to substituted N-phenyl-N-aminouracils of general formula (I) or salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for co...
|
|
WO/2021/000041A1 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery ...
|
|
WO/2020/263994A1 |
The present invention discloses a liquid, propellant-free pharmaceutical formulation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutic...
|
|
WO/2020/252589A1 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...
|
|
WO/2020/248076A1 |
Disclosed are methods for separating, recovering, and purifying cannabidiolic acid (CBDA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in C5-C7...
|
|
WO/2020/248077A1 |
Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids...
|
|
WO/2020/252222A1 |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).
|
|
WO/2020/216766A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...
|
|
WO/2020/117637A1 |
The present invention is directed to derivatives and prodrugs of quinuclidine-ring containing compounds. The present invention is further directed to ophthalmo!ogical compositions comprising a therapeutically effective amount of a compou...
|
|
WO/2020/096909A1 |
Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox
y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt. Provi...
|
|
WO/2020/096911A1 |
Provided herein are methods of producing the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox
y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt.
|
